| Theme | The New Guideline for Liver Cancer Treatment | |
|---|---|---|
| Title | Prevention of Hepatocellular Carcinoma | |
| Publish Date | 2018/06 | |
| Author | Yutaka Yasui | Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital |
| Author | Namiki Izumi | Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital |
| [ Summary ] | Hepatocellular carcinoma (HCC) could develop upon chronic liver disease such as viral hepatitis and non-alcoholic steatohepatitis (NASH). Nucleot(s)ide analogue are clarified to reduce the risk of HCC development. In hepatitis C patients, direct acting antivirals (DAAs) have improved success rate of antiviral therapy. DAAs have also been reported to decrease HCC risk recently. On the other hand, HCC development in NASH patients has been increasing since several decades. Treatment for diabetes or hyperlipidemia are reported to be important for preventing NASH-HCC. Chronic hepatitis patients should be managed according to the etiology to prevent HCC development. | |